Company
Polaryx Therapeutics, Inc. (PLYX)
Standardized SEC financial data for Polaryx Therapeutics, Inc. — income statement, balance sheet, cash flow and 40+ ratios, as a clean JSON API. CIK 0002075320 · NASDAQ · Pharmaceutical Preparations.
Return on equity
-196.8%
Free cash flow
-$3.9M
Current ratio
8.54×
EPS (diluted)
$-0.20
Income statement
| USD | FY2024 | FY2025 |
|---|---|---|
| R&D expense | $2.8M | $6.3M |
| SG&A expense | $1.5M | $1.6M |
| Operating income | -$4.4M | -$7.8M |
| Pretax income | -$30.4M |
Balance sheet
| USD | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Cash & equivalents | — | $4.6M | $5.1M |
| Total current assets | — | $5.0M | $5.2M |
| Total assets | — | $5.0M |
Cash flow
| USD | FY2024 | FY2025 |
|---|---|---|
| Operating cash flow | -$2.6M | -$3.9M |
| Financing cash flow | $7.2M | $4.5M |
| Dividends paid | $0 | $0 |
Get PLYX data via API
# JSON
curl https://sec-financial-api-production.up.railway.app/v1/company/PLYX/financials \
-H "X-API-Key: YOUR_KEY"
# CSV export (income / balance / cash-flow)
curl "https://sec-financial-api-production.up.railway.app/v1/company/PLYX/income-statement?format=csv" \
-H "X-API-Key: YOUR_KEY"